Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Isabelle Henskens
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07146295CT.gov Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer | — | Recruiting | — | — | — |
NCT06327490CT.gov A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer | — | Recruiting | — | — | — |
NCT06347354CT.gov Permanence of Indocyanine Green in Axillary Lymph Nodes 3 Weeks After Subdermal Injection in Patients With Breast Cancer and Metastatic Lymph Nodes | — | Unknown | — | — | — |
NCT06227338CT.gov ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study | — | Recruiting | — | — | — |
NCT06024213CT.gov A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy. | — | Completed | — | — | — |
NCT05094102CT.gov Intraoperative Evaluation of Axillary Lymphatics | — | Completed | — | — | — |
NCT05623280CT.gov Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node. | — | Unknown | — | — | — |
NCT03941756CT.gov Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | — | Recruiting | — | — | — |
NCT03579979CT.gov Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG | — | Completed | — | — | — |
NCT02994225CT.gov Axillary Reverse Mapping Using Near-infrared Imaging in Invasive Breast Cancer: Predictors of Nodal Positivity | — | Completed | — | — | — |
Show 15 more trialsShow fewer
NCT02817334CT.gov A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer | — | Unknown | — | — | — |
NCT02479997CT.gov Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients | — | Completed | — | — | — |
NCT02473159CT.gov Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer | — | Unknown | — | — | — |
NCT02419807CT.gov Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer | — | Completed | — | — | — |
NCT02415725CT.gov Early Detection of Lymphedema After Cancer Treatments | — | Unknown | — | — | — |
NCT02316795CT.gov Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma | — | Completed | — | — | — |
NCT02027818CT.gov Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy | — | Completed | — | — | — |
NCT02084784CT.gov Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research | — | Completed | — | — | — |
NCT02032563CT.gov Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy | — | Unknown | — | — | — |
NCT02032498CT.gov Evaluation of Two Techniques for the SLN Detection in BC Patients | — | Unknown | — | — | — |
NCT01969448CT.gov Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction | — | Completed | — | — | — |
NCT01993576CT.gov ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue. | — | Completed | — | — | — |
NCT01771666CT.gov Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer | — | Completed | — | — | — |
NCT01276054CT.gov Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients. | — | Terminated | — | — | — |
NCT01095913CT.gov Fluorescent Dyes for Lymph Node Mapping | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Indocyanine Green (this asset) | Isabelle Henskens | P3 | B · 61 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Indocyanine Green
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Endometrial Carcinoma | — | P4 | BB · 70 |
| Vulva Cancer | — | P4 | BB · 70 |
| Rectal Cancer | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Indocyanine Green in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/indocyanine-green-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →